Articles: human.
-
Clin J Am Soc Nephrol · Jun 2017
Multicenter StudySleep and CKD in Chinese Adults: A Cross-Sectional Study.
To assess the association between self-reported sleep duration and quality and odds of having CKD in Chinese adults on the basis of a community study. ⋯ Worse overall sleep quality was associated with higher odds of being high or very high risk for CKD and proteinuria in Chinese adults.
-
Randomized Controlled Trial Multicenter Study
Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.
The calcitonin gene-related peptide (CGRP) pathway is important in migraine pathophysiology. We assessed the efficacy and safety of erenumab, a fully human monoclonal antibody against the CGRP receptor, in patients with chronic migraine. ⋯ Amgen.
-
Journal of neurotrauma · May 2017
Randomized Controlled Trial Multicenter StudyRepetitive intermittent hypoxia and locomotor training enhances walking function in incomplete spinal cord injury subjects: A randomized, triple-blind, placebo-controlled clinical trial.
Incomplete spinal cord injuries (iSCI) leave spared synaptic pathways below the level of injury. Intermittent hypoxia (IH) elicits plasticity in the spinal cord and strengthens spared synaptic pathways, expressed as respiratory and somatic functional recovery in experimental animals and humans with iSCI. This study is a randomized, triple-blind, two-arm parallel clinical trial performed in Santiago, Chile. ⋯ We conclude that daily IH enhances walking recovery in subjects with iSCI, confirming previous findings. Moreover, 3 × wIH prolonged or enhanced daily IH-induced walking speed and endurance improvements, respectively, up to 5 weeks post-daily IH. Repetitive IH may be a safe and effective therapeutic alternative for persons with iSCI.
-
The lancet oncology · May 2017
Multicenter StudyNivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial.
Nivolumab is a human monoclonal IgG4 antibody that inhibits programmed cell death protein 1 (PD-1) expressed on activated T cells. We investigated the safety and activity of nivolumab in patients with treatment-refractory oesophageal cancer. ⋯ Ono Pharmaceutical, Bristol-Myers Squibb.
-
Randomized Controlled Trial Multicenter Study
Immunogenicity of 2 vs 3 Doses of the Quadrivalent Human Papillomavirus Vaccine in Girls Aged 9 to 13 Years After 60 Months.